{"id":"sham-avastin-intravitreal-injection","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sham Avastin refers to a placebo comparator in phase 3 clinical trials evaluating intravitreal bevacizumab (Avastin). The sham injection mimics the administration procedure of the active drug but delivers an inert substance, allowing researchers to isolate the true therapeutic effect of bevacizumab from procedural and expectation effects in ophthalmologic conditions.","oneSentence":"This is a sham (placebo) intravitreal injection used as a control in clinical trials, containing no active pharmaceutical ingredient.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:16.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sham control arm in phase 3 trials (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT01940887","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-05","conditions":"Age-Related Macular Degeneration","enrollment":645},{"nctId":"NCT06191094","phase":"PHASE4","title":"Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy","status":"ENROLLING_BY_INVITATION","sponsor":"University of Colorado, Denver","startDate":"2024-07-12","conditions":"Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus","enrollment":100},{"nctId":"NCT01716026","phase":"PHASE3","title":"Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2012-10","conditions":"Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia","enrollment":66},{"nctId":"NCT05582577","phase":"PHASE2, PHASE3","title":"Additional Effect of Subthreshold Micropulse Laser to Intravitreous Injection of Bevacizumab on Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2022-10-15","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT03203447","phase":"PHASE3","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","status":"TERMINATED","sponsor":"Clearside Biomedical, Inc.","startDate":"2018-03-05","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":325},{"nctId":"NCT02229175","phase":"PHASE2, PHASE3","title":"Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2021-01-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT02348918","phase":"PHASE2","title":"Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allegro Ophthalmics, LLC","startDate":"2014-10-13","conditions":"Diabetic Macular Edema","enrollment":218},{"nctId":"NCT01270542","phase":"NA","title":"Avastin for PDR (Proliferative Diabetic Retinopathy)","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2009-06","conditions":"Retinal Detachment, Diabetic Retinopathy","enrollment":20},{"nctId":"NCT00336323","phase":"PHASE2","title":"A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2006-06","conditions":"Diabetic Retinopathy","enrollment":121},{"nctId":"NCT00682539","phase":"PHASE4","title":"Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Diabetic Macular Edema","enrollment":71},{"nctId":"NCT02308644","phase":"PHASE3","title":"Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-02","conditions":"Diabetic Macular Edema","enrollment":41},{"nctId":"NCT01854593","phase":"PHASE4","title":"Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Nihon University","startDate":"2012-05","conditions":"Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment, Vitreous Hemorrhage","enrollment":69},{"nctId":"NCT02140450","phase":"NA","title":"Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection","status":"COMPLETED","sponsor":"Mashhad University of Medical Sciences","startDate":"2012-02","conditions":"Intraocular Pressure Change in Intravitreal Injection","enrollment":70},{"nctId":"NCT00970957","phase":"PHASE3","title":"Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2009-09","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":107},{"nctId":"NCT00906685","phase":"PHASE3","title":"Bevacizumab for Central Retinal Vein Occlusion Study","status":"COMPLETED","sponsor":"Anders Kvanta","startDate":"2009-05","conditions":"Central Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT00370851","phase":"PHASE3","title":"Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-08","conditions":"Retinal Disease","enrollment":82},{"nctId":"NCT00524875","phase":"NA","title":"Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2007-01","conditions":"Diabetic Retinopathy","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sham"],"phase":"phase_3","status":"active","brandName":"Sham Avastin Intravitreal Injection","genericName":"Sham Avastin Intravitreal Injection","companyName":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","companyId":"instituto-universitario-de-oftalmobiolog-a-aplicada-institute-of-applied-ophthal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a sham (placebo) intravitreal injection used as a control in clinical trials, containing no active pharmaceutical ingredient. Used for Sham control arm in phase 3 trials (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}